Cytotoxic agents for use in dermatology. I

Journal of the American Academy of Dermatology

Volumn 12, Issue 5, 1985, Pages 753-775

  McDonald, Charles J ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBENZOIC ACID; ACICLOVIR; ALLOPURINOL; ANTINEOPLASTIC AGENT; CHLORAMPHENICOL; CORTICOSTEROID; CYTOSTATIC AGENT; CYTOTOXIC AGENT; FOLINATE CALCIUM; IDOXURIDINE; PHENYLBUTAZONE; PHENYTOIN; PROBENECID; SALICYLIC ACID DERIVATIVE; SULFANILAMIDE DERIVATIVE; TETRACYCLINE; VIDARABINE;

ADVERSE DRUG REACTION; ALOPECIA; BLADDER; BLOOD AND HEMOPOIETIC SYSTEM; BONE MARROW DEPRESSION; DIGESTIVE SYSTEM; DRUG HALF LIFE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HEMORRHAGIC CYSTITIS; HUMAN; INTOXICATION; KIDNEY; LYMPHOMA; NEPHROTOXICITY; NERVOUS SYSTEM; NEUROTOXICITY; PEMPHIGUS VULGARIS; PERIPHERAL VASCULAR SYSTEM; PHARMACOKINETICS; PHARMACOLOGY; PRIORITY JOURNAL; PROGRESSIVE SYSTEMIC SCLEROSIS; PSORIASIS; REVIEW; SARCOIDOSIS; SKIN TOXICITY; VASCULITIS;

ALKYLATING AGENTS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CHEMISTRY; HUMAN; METHOTREXATE; PSORIASIS; SKIN DISEASES; SUPPORT, NON-U.S. GOV'T; VINCA ALKALOIDS;

EID: 0021824937     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0190-9622(85)70097-7     Document Type: Article

References (114)

1. Pemphigus: A 20-year review of 107 patients treated with corticosteroids
2. Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs
3. Immunosuppression and skin cancer
4. Skin tumours in immunosuppressed patients
5. DNA repair
6. Defective DNA endonuclease activity on anthra-mycin treated DNA in xeroderma pigmentosum and mouse melanoma cells
7. Mechanisms of action of 2-chlorethyl-amine derivatives, sulfur mustards, epoxides and azauridine
8. Molecular biology of alkylation: An overview
9. Alkylating agents, antimetabolites, hormones and other antiproliferative agents
10. Topical mechlorethamine chemotherapy
11. Frequent low doses of intravenous mechlorethamine for late-stage mycosis fungoides lymphoma
12. Effect of aging aqueous nitrogen mustard on white blood cell count, body weight and Walker 256 tumor in the rat
13. Mechlorethamine hydrochloride solution and ointment
14. Alternative modes of cyclophosphamide and azathioprine therapy in lupus nephritis
15. The treatment of mycosis fungoides with ointment-based mechlorethamine
16. Topical mustine hydrochloride and psoriasis: A follow-up study
17. 2)
18. Effects of topical mechlorethamine on skin lesions of psoriasis
19. Topical nitrogen mustard induced carcinogenesis
20. Parenteral methotrexate in psoriasis
21. Parenteral methotrexate in psoriasis
22. Treatment of pemphigus vulgaris with methotrexate
23. Polymyositis and dermatomyositis: Combined methotrexate and corticosteroid therapy
24. Treatment of dermatomyositis
25. Folate antagonists
26. The treatment ot leukemia with large doses of methotrexate and folinic acid: Clinical-biochemical correlates
27. Quantitative and cytokinetic studies in experimental tumor models
28. Methotrexate guidelines —revised
29. Treatment of mycosis fungoides lymphoma : Effectiveness of infusions of methotrexate followed by oral citrovorum factor
30. Methotrexate therapy of head and neck cancer: Improvement in therapeutic index by the use of leucovorin “rescue”
31. Phase I study of high doses of methotrexate with citrovorum factor in patients with lung cancer
32. Recent advances in the chemotherapy of metastatic osteogenic sarcoma
33. Psoriasis-liver-methotrexate interactions
34. Liver disease in psoriasis. An effect of methotrexate therapy?
35. Beneficial effects of triacetyl-6-azauridine in psoriasis and mycosis fungoides
36. Combination chemotherapy for recalcitrant psoriasis
37. Highly effective and safe therapy for resistant psoriasis with low-dose 5-fluorouracil
38. Clinical studies with systemic administration of antimetabolites of pyrimidine nucleosides in viral infections
39. A trial of topical acyclovir in genital herpes simplex virus infections
40. Chemotherapy of systemic mycosis
41. Azaribine for mycosis fungoides
42. Fluorinated pyrimidines and their nucleosides
43. Halogenated pyrimidine deoxyribonucleosides
44. Treatment of herpes keratitis with 5-iodo-2′-deoxyuridine (IDU): A clinical evaluation of 1500 cases
45. Boston In-terhospital Virus Study Group and the NIAID-sponsored cooperative antiviral study. Failure of high dose 5-iodo- 2′-deoxyuridine in the therapy of herpes simplex virus encephalitis
46. Nucleoside analogs in the treatment of neoplastic diseases
47. The pharmacological and immunological basis for the use of immunosuppressive drugs
48. The immunosuppressive mechanism of azathioprine. I. In vitro effect of lymphocyte function in the baboon.
49. Immunosuppression with azathioprine, prednisone and cyclophosphamide
50. Acyclovir comes of age
51. Biochemistry and pharmacology of purine analogs
52. Azathioprine
53. Treatment of psoriasis with mercaptopurine
54. Treatment of psoriatic arthritis with 6-mercaptopurine
55. Azathioprine in psoriasis
56. Azathioprine therapy of autoimmune diseases
57. Pemphigus treatment with azathioprine: Clinical and immunologic correlation
58. Azathioprine for pemphigus and pemphigoid; A four year follow up study
59. Immunosuppressive therapy in collagen vascular diseases
60. Prognostic indices in lupus nephritis
61. Immunosuppressive agents in corticosteroid-refractory childhood dermatomyositis
62. Azathioprine therapy in polymyositis
63. Immunosuppressive and corticosteroid therapy for polyarteritis nodosa
64. Selectivity of action of an antiherpetic agent 9-(2-hydroxyethoxy-methy!)guanine
65. 9-(2-Hydroxyethoxymethyl)guanine activity against viruses of the herpes group
66. Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound 9-(2-hydroxyethoxymethyl)-guanine
67. Phosphorylation of acyclovir (acyclo-guanosine) monophosphate by GMP kinase
68. Inhibition of herpes simplex virus-induced DNA polymerase activity and viral DNA replication by 9-(2-hydroxyethoxy-methyl)guanine and its triphosphate
69. Inhibition of purified human and herpes simplex virus-induced DNA polymerases by 9-(2-hydroxyethoxymethyl)guanine triphosphate, Effects on primer-template function
70. In vitro susceptibility of varicella-zoster virus to acyclovir
71. Effect of acyclovir [9-(2-hydroxyethoxymethyl)guanine] on Epstein-Barr virus replication
72. Growth inhibition by acycloguanosine of herpes viruses isolated from human infections
73. The in vitro activity of acyclovir and related compounds against cytomegalovirus infections
74. Perspectives on interactions of acyclovir with Epstcin-Barr and other herpes viruses
75. Phosphorylation of acyclovir by a thymidine kinase induced by varicella-zoster virus
76. Acyclovir inhibition of Epstein-Barr virus replication
77. Novel substrate of adenosine deaminase
78. Human pharmacokinetics of acyclovir (an antiviral agent) following rapid intravenous injection
79. Acyclovir kinetics after intravenous infusion
80. Latent herpes simplex virus infections in sensory ganglia of hairless mice prevented by acycloguanosine
81. Efficacy of acycloguanosine (Wellcome 284U) against herpes simplex corneal ulcers
82. Randomized double-blind trial of acyclovir and idoxuridine in dendritic corneal ulceration
83. Comparative trial of acyclovir and adenine arabinoside in the treatment of herpes simplex corneal ulcers
84. Acyclovir prophylaxis of herpes simplex virus infections. A randomized double-blind controlled trial in bone-marrow-transplant recipients
85. Intravenous acyclovir to treat mucocutaneous herpes simplex virus infections after marrow transplantation. A double-blind trial
86. Acyclovir for chronic mucocutaneous herpes simplex virus infection in immunosuppressed patients
87. Treatment of eczema herpeticum with acyclovir
88. Treatment of first episode of genital herpes simplex virus infection with oral acyclovir. A randomized double-blind controlled trial in normal subjects
89. Transient renal impairment during intravenous acyclovir therapy
90. Parenteral acyclovir therapy for herpes-virus infections in man
91. Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir
92. Isolation and characterization of resistant herpes simplex virus after acyclovir therapy
93. Two distinct loci confer resistance to acycloguanosine in herpes simplex virus type 1
94. Resistance of herpes simplex virus to acycloguanosine: Role of viral thymidine kinase and DNA polymerase loci
95. Treatment of Kaposi's sarcoma with vinblastine
96. Vinca alkaloids and colchicine
97. Recent studies on biochemistry and action of bleomycin
98. A review of the survival and cell-kinetic effects of bleomycin
99. Clinical pharmacology of bleomycin
100. Intracellular fate and activity of bleomycin
101. Hydroxyurea: A new agent for the management of refractory psoriasis
102. Psoriasis with hydroxyurea. An 18-month study of 60 patients
103. Effect of hydroxyurea on T4 ribonucleotide reductase
104. Clinical and pharmacological effects of hydroxyurea
105. 14
106. Hydroxyurea (NSC032065) in biological fluids: Dose-concentration relationship
107. Effects of methotrexate and hydroxyurea on psoriatic epidermis. Preferential cytotoxic effects on psoriatic epidermis
108. Megaloblastic erythropoiesis induced by hydroxyurea (NSC032065)
109. Severe reaction to hydroxyurea
110. Renal tubular abnormalities induced by hydroxyurea (NSC-32065)
111. Megaloblastic anemia in the management of severe psoriasis
112. Preliminary survey of hydroxyurea (NSC-32065) as a teratogen
113. Hydroxyurea: Induction of breaks in template strands of replicating DNA